// App-Quantinova.ai

4274 : Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Researchers

Presenter

  • Alejandro Lazo-Langner

Principal Investigators

  • Anargyros Xenocostas

  • Ian H. Chin-Yee

  • Kang Howson-Jan

  • David Sanford

  • Cyrus C. Hsia

Medical Centers

  • Department of Medicine, University of Western Ontario, London, ON, Canada

  • Department of Hematology, London Health Sciences Centre - Victoria Hospital, London, ON, Canada

  • Department of Hematology, London Health Sciences Centre - Victoria Hospital, London, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved